Ridgecrest Wealth Partners’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$603K Buy
4,325
+75
+2% +$10.5K 0.33% 51
2025
Q4
$522K Sell
4,250
-54
-1% -$6.56K 0.28% 56
2025
Q3
$478K Hold
4,304
0.22% 66
2025
Q2
$477K Sell
4,304
-300
-7% -$31.9K 0.25% 63
2025
Q1
$516K Sell
4,604
-14
-0.3% -$1.45K 0.27% 60
2024
Q4
$427K Buy
4,618
+12
+0.3% +$1.08K 0.23% 65
2024
Q3
$386K Buy
4,606
+150
+3% +$11.4K 0.2% 75
2024
Q2
$306K Hold
4,456
0.18% 81
2024
Q1
$326K Hold
4,456
0.19% 78
2023
Q4
$361K Sell
4,456
-637
-13% -$49.6K 0.24% 69
2023
Q3
$382K Hold
5,093
0.27% 61
2023
Q2
$393K Buy
5,093
+302
+6% +$24.1K 0.26% 63
2023
Q1
$398K Hold
4,791
0.28% 59
2022
Q4
$411K Hold
4,791
0.31% 57
2022
Q3
$296K Sell
4,791
-440
-8% -$27.7K 0.24% 72
2022
Q2
$323K Sell
5,231
-250
-5% -$15.5K 0.24% 75
2022
Q1
$326K Sell
5,481
-1,000
-15% -$63.9K 0.21% 85
2021
Q4
$471K Sell
6,481
-174
-3% -$12K 0.23% 76
2021
Q3
$465K Buy
6,655
+100
+2% +$7.03K 0.25% 72
2021
Q2
$451K Buy
6,555
+300
+5% +$20K 0.28% 67
2021
Q1
$404K Buy
+6,255
New +$403K 0.39% 55

Other funds holding GILD

Ridgecrest Wealth Partners's GILD Position: Q1 2026 in Review

Ridgecrest Wealth Partners increased its Gilead Sciences (GILD) stake by 1.8% in Q1 2026, buying an estimated $10.5K and bringing the position to 4,325 shares worth $603K. The position accounts for 0.33% of the portfolio, ranked #51.

Ridgecrest Wealth Partners first reported a position in GILD in Q1 2021 and has held it in 21 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Ridgecrest Wealth Partners held 4,325 shares of Gilead Sciences worth $603K as of Q1 2026.
  • Ridgecrest Wealth Partners bought 75 Gilead Sciences shares in Q1 2026, an estimated $10.5K.
  • Gilead Sciences made up 0.33% of Ridgecrest Wealth Partners's portfolio in Q1 2026, its #51 holding.
  • Ridgecrest Wealth Partners first reported a position in Gilead Sciences in Q1 2021 and has held it in 21 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Ridgecrest Wealth Partners's 13F filing for Q1 2026, filed 22 Apr 2026.